75 related articles for article (PubMed ID: 21355002)
21. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
[TBL] [Abstract][Full Text] [Related]
22. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
23. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
25. The role of paclitaxel in the management of patients with carcinoma of the cervix.
Thigpen T; Vance R; Khansur T; Malamud F
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-41-S2-46. PubMed ID: 9045336
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group.
Mannel RS; Blessing JA; Boike G
Gynecol Oncol; 2000 Oct; 79(1):64-6. PubMed ID: 11006033
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin, cyclophosphamide, and 5-fluorouracil in patients with carcinoma of the cervix or vagina.
Piver MS; Barlow JJ; Dunbar J
Cancer Treat Rep; 1980; 64(4-5):549-51. PubMed ID: 7000344
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy for recurrent and metastatic cervical cancer.
Tao X; Hu W; Ramirez PT; Kavanagh JJ
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239
[TBL] [Abstract][Full Text] [Related]
29. Topotecan demonstrates significant activity in recurrent small-cell lung cancer.
Oncology (Williston Park); 1996 Jan; 10(1):111. PubMed ID: 8924362
[No Abstract] [Full Text] [Related]
30. A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
Kang JH; Lee KH; Kim DW; Kim SW; Kim HR; Kim JH; Choi JH; An HJ; Kim JS; Jang JS; Kim BS; Kim HT
Br J Cancer; 2021 Feb; 124(4):713-720. PubMed ID: 33191408
[TBL] [Abstract][Full Text] [Related]
31. [Present-day potential of medication for disseminated cervical carcinoma].
Moiseenko VM; Teletaeva GM; Orlova RV; Urmancheeva AF; Ermakova NA; Protsenko SA; Mikhaĭlichenko TD
Vopr Onkol; 2004; 50(3):304-10. PubMed ID: 15318703
[No Abstract] [Full Text] [Related]
32. A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.
Kim HS; Park SY; Park CY; Kim YT; Kim BJ; Song YJ; Kim BG; Kim YB; Cho CH; Kim JH; Song YS
Br J Cancer; 2021 Jan; 124(2):375-382. PubMed ID: 32994466
[TBL] [Abstract][Full Text] [Related]
33. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.
Raymond E; Campone M; Stupp R; Menten J; Chollet P; Lesimple T; Fety-Deporte R; Lacombe D; Paoletti X; Fumoleau P; ; ;
Eur J Cancer; 2002 Jul; 38(10):1348-50. PubMed ID: 12091065
[TBL] [Abstract][Full Text] [Related]
34. Topoisomerase-I inhibitors in gynaecologic tumours.
Verschraegen CF; Kudelka AP; Kavanagh JJ
Ann Acad Med Singap; 1998 Sep; 27(5):683-7. PubMed ID: 9919340
[TBL] [Abstract][Full Text] [Related]
35. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.
Munster PN; Daud AI
Expert Opin Investig Drugs; 2011 Nov; 20(11):1565-74. PubMed ID: 21985236
[TBL] [Abstract][Full Text] [Related]
36. 5-aza-2'-deoxycytidine in advanced or recurrent cancer of the uterine cervix.
Vermorken JB; Tumolo S; Roozendaal KJ; Guastalla JP; Splinter TA; Renard J
Eur J Cancer; 1991; 27(2):216-7. PubMed ID: 1709026
[No Abstract] [Full Text] [Related]
37. Clonal analysis of cancer cells that survived anticancer drug treatment.
Tanaka T; Chang L; Umesaki N; Ogita S
Osaka City Med J; 1997 Dec; 43(2):259-65. PubMed ID: 9540347
[TBL] [Abstract][Full Text] [Related]
38. Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs.
Verschraegen CF; Gilbert BE; Huaringa AJ; Newman R; Harris N; Leyva FJ; Keus L; Campbell K; Nelson-Taylor T; Knight V
Ann N Y Acad Sci; 2000; 922():352-4. PubMed ID: 11193921
[No Abstract] [Full Text] [Related]
39. [Development of new anti-cancer agents in Europe].
Terada K
Gan To Kagaku Ryoho; 1996 Jan; 23(2):231-7. PubMed ID: 8611052
[TBL] [Abstract][Full Text] [Related]
40. Further experience with hexamethylmelamine (NSC-13875) in the treatment of carcinoma of the cervix.
Stolinsky DC; Bateman JR
Cancer Chemother Rep; 1973; 57(4):497-9. PubMed ID: 4586957
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
